{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:29:14Z","timestamp":1771342154675,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Real-world treatment patterns and clinical outcomes for patients with lower-risk myelodysplastic syndromes (LR-MDS) in Japan are insufficiently characterized. This study assessed treatment patterns, clinical outcomes, costs, and healthcare resource utilization of patients with LR-MDS in Japan using the AsMedix electronic health record database. The study included 177 patients aged\u2009\u2265\u200918\u00a0years with LR-MDS, identified between April 1, 2017, and March 31, 2022. Of these, 79 were transfusion dependent (TD) and 98 were non-transfusion dependent (NTD). Treatment patterns were diverse, and 57 (32.2%) patients received hypomethylating agents (combination or monotherapy) as first-line treatment. Median (95% confidence interval) overall survival was 32.6\u00a0months (17.6\u2013not evaluable) among TD patients who achieved red blood cell transfusion independence (RBC-TI)\u2009\u2265\u20098\u00a0weeks during weeks 1\u201324, compared with 22.3\u00a0months (10.1\u2013not evaluable) among those who did not (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.17). Among NTD patients, maintaining NTD status was also associated with longer median overall survival. Furthermore, patients who achieved or maintained RBC-TI incurred roughly half the monthly medical costs per individual compared with those who did not, highlighting the clinical and economic importance of reducing RBC transfusion requirements. Further research is needed to understand the impacts of treatment on patients with LR-MDS-related anemia in Japan.\n                  <\/jats:p>","DOI":"10.1007\/s12185-025-04077-y","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:45:47Z","timestamp":1759398347000},"page":"196-207","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns and outcomes of patients with LR-MDS in Japan: an electronic health record database study"],"prefix":"10.1007","volume":"123","author":[{"given":"Shuji","family":"Uno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuko","family":"Nakakoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Midorikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Tajiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Minehata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"4077_CR1","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"4077_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000314","volume":"3","author":"U Germing","year":"2019","unstructured":"Germing U, Oliva EN, Hiwase D, Almeida A. Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies. HemaSphere. 2019;3:e314.","journal-title":"HemaSphere"},{"key":"4077_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/jha2.523","volume":"3","author":"M Meunier","year":"2022","unstructured":"Meunier M, Park S. Lower-risk myelodysplastic syndromes: current treatment options for anemia. EJHaem. 2022;3:1091\u20139.","journal-title":"EJHaem"},{"key":"4077_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41408-022-00765-8","volume":"12","author":"AM Brunner","year":"2022","unstructured":"Brunner AM, Leitch HA, van de Loosdrecht AA, Bonadies N. Management of patients with lower-risk myelodysplastic syndromes. Blood Cancer J. 2022;12:166.","journal-title":"Blood Cancer J"},{"key":"4077_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.leukres.2012.01.006","volume":"36","author":"U Platzbecker","year":"2012","unstructured":"Platzbecker U, Hofbauer LC, Ehninger G, H\u00f6lig K. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res. 2012;36:525\u201336.","journal-title":"Leuk Res"},{"key":"4077_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/hematology.2019000040","volume":"2019","author":"MA Sekeres","year":"2019","unstructured":"Sekeres MA, Patel BJ. Lowering the boom on lower-risk myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program. 2019;2019:367\u201372.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"4077_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.967900","volume":"9","author":"SK Toprak","year":"2022","unstructured":"Toprak SK. Past, present and future in low-risk myelodysplastic syndrome. Front Med Lausanne. 2022;9:967900.","journal-title":"Front Med Lausanne"},{"key":"4077_CR8","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1002\/cncr.21860","volume":"106","author":"L Balducci","year":"2006","unstructured":"Balducci L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer. 2006;106:2087\u201394.","journal-title":"Cancer"},{"key":"4077_CR9","unstructured":"Ministry of Health, Labour and Welfare. Guidelines for the use of blood products. https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-11120000-Iyakushokuhinkyoku\/0000161115.pdf. (in Japanese). Accessed 1 Nov 2024."},{"key":"4077_CR10","unstructured":"Japanese Society of Hematology. Guidelines for the treatment of hematopoietic tumors. http:\/\/www.jshem.or.jp\/gui-hemali\/table.html (in Japanese). Accessed 13 Mar 2025."},{"key":"4077_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10147-024-02510-6","volume":"29","author":"N Matsumura","year":"2024","unstructured":"Matsumura N, Mandai M. PMDA regulatory update on approval of new drugs and revisions of precautions; approval of talazoparib tosilate for prostate and breast cancer, and luspatercept for myelodysplastic syndrome in Japan. Int J Clin Oncol. 2024;29:493\u20134.","journal-title":"Int J Clin Oncol"},{"key":"4077_CR12","unstructured":"Bristol Myers Squibb. Reblozyl (luspatercept) package insert. Revised 2024. https:\/\/packageinserts.bms.com\/pi\/pi_reblozyl.pdf. Accessed 1 Nov 2024."},{"key":"4077_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/fon-2021-0988","volume":"18","author":"S Tsutsu\u00e9","year":"2022","unstructured":"Tsutsu\u00e9 S, Suzuki T, Kim H, Crawford B. Real-world assessment of myelodysplastic syndrome: Japanese claims data analysis. Future Oncol. 2022;18:93\u2013104.","journal-title":"Future Oncol"},{"key":"4077_CR14","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079\u201388.","journal-title":"Blood"},{"key":"4077_CR15","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sol\u00e9 F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"4077_CR16","unstructured":"Uno S, et al. Poster presentation at the 86th annual meeting of the Japanese Society of Hematology (JSH). Kyoto, Japan; October 11\u201313; 2024. Poster P-1-5-1."},{"key":"4077_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2188\/jea.JE20140042","volume":"24","author":"D Chihara","year":"2014","unstructured":"Chihara D, Ito H, Katanoda K, Shibata A, Matsuda T, Sobue T, et al. Incidence of myelodysplastic syndrome in Japan. J Epidemiol. 2014;24:469\u201373.","journal-title":"J Epidemiol"},{"key":"4077_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12185-017-2250-0","volume":"106","author":"H Kawabata","year":"2017","unstructured":"Kawabata H, Tohyama K, Matsuda A, Araseki K, Hata T, Suzuki T, et al. Validation of the revised international prognostic scoring system in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry. Int J Hematol. 2017;106:375\u201384.","journal-title":"Int J Hematol"},{"key":"4077_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.leukres.2018.08.022","volume":"73","author":"Y Miyazaki","year":"2018","unstructured":"Miyazaki Y, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Sol\u00e9 F, et al. Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: analysis from the international working group for prognosis of MDS. Leuk Res. 2018;73:51\u20137.","journal-title":"Leuk Res"},{"key":"4077_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s12185-013-1485-7","volume":"99","author":"K Nakazaki","year":"2014","unstructured":"Nakazaki K, Nannya Y, Kurokawa M. Distribution of serum erythropoietin levels in lower risk myelodysplastic syndrome cases with anemia. Int J Hematol. 2014;99:53\u20136.","journal-title":"Int J Hematol"},{"key":"4077_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12185-014-1699-3","volume":"101","author":"T Suzuki","year":"2015","unstructured":"Suzuki T, Oh I, Ohmine K, Meguro A, Mori M, Fujiwara S, et al. Distribution of serum erythropoietin levels in Japanese patients with myelodysplastic syndromes. Int J Hematol. 2015;101:32\u20136.","journal-title":"Int J Hematol"},{"key":"4077_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.17652","volume":"195","author":"M Alonso-Fernandez-Gatta","year":"2021","unstructured":"Alonso-Fernandez-Gatta M, Martin-Garcia A, Martin-Garcia AC, Lopez-Cadenas F, Diaz-Pelaez E, Jimenez-Solas T, et al. Predictors of cardiovascular events and all-cause of death in patients with transfusion-dependent myelodysplastic syndrome. Br J Haematol. 2021;195:536\u201341.","journal-title":"Br J Haematol"},{"key":"4077_CR23","unstructured":"National Cancer Research Center. List of clinical test standard values. 2013. https:\/\/www.ncc.go.jp\/jp\/ncch\/division\/clinical_trial\/info\/clinical_trial\/professional\/Rinshou\/kijunchi_ichiran_1304.pdf (in Japanese). Accessed 8 Dec 2024."},{"key":"4077_CR24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12185-022-03414-9","volume":"116","author":"Y Morita","year":"2022","unstructured":"Morita Y, Nannya Y, Ichikawa M, Hanamoto H, Shibayama H, Maeda Y, et al. ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-jhs mds01 trial. Int J Hematol. 2022;116:659\u201368.","journal-title":"Int J Hematol"},{"key":"4077_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13092702","volume":"13","author":"R Boccia","year":"2024","unstructured":"Boccia R, Xiao H, von Wilamowitz-Moellendorff C, Raorane R, Deshpande S, Klijn SL, et al. A systematic literature review of predictors of erythropoiesis-stimulating agent failure in lower-risk myelodysplastic syndromes. J Clin Med. 2024;13:2702.","journal-title":"J Clin Med"},{"key":"4077_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s12185-024-03872-3","volume":"121","author":"H Kosugi","year":"2025","unstructured":"Kosugi H, Fujisaki T, Iwasaki H, Shinagawa A, Iida H, Jo T, et al. A phase 2 clinical trial of luspatercept in non-transfusion-dependent patients with myelodysplastic syndromes. Int J Hematol. 2025;121:68\u201378.","journal-title":"Int J Hematol"},{"key":"4077_CR27","unstructured":"Bristol Myers Squibb. Reblozyl (luspatercept) package insert. Revised 2024. (in Japanese). Accessed 8 Dec 2024."},{"key":"4077_CR28","first-page":"338","volume":"38","author":"ME Edmondson","year":"2020","unstructured":"Edmondson ME, Reimer AP. Challenges frequently encountered in the secondary use of electronic medical record data for research. Comput Inform Nurs. 2020;38:338\u201348.","journal-title":"Comput Inform Nurs"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04077-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04077-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04077-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T14:50:38Z","timestamp":1771339838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04077-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4077"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04077-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TS reports BMS: consultancy, honoraria; Kyowa Kirin: honoraria; Nippon Shinyaku: honoraria; Novartis: honoraria. MN, SM, JH, JH, KM, SU report BMS: employment and stock options. TK and RT report employment at Mebix, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}